GP88 Protein Shows Promise As Basis for Both Diagnostic Test and Therapeutic for Breast Cancer | GenomeWeb

BOSTON — A new protein that can serve as both a drug target and a diagnostic biomarker for breast cancer was presented here this week at the Biomarker Pipeline conference.

The new protein, called GP88, was developed by the 5-year-old Columbia, Md.-based company A&G Pharmaceutical.

“From the beginning it was my intention to identify a target that had both diagnostic and therapeutic potential,” Ginette Serrero, the president and chief scientific officer of the company, told ProteoMonitor. “That was not an accident.”

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.

Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.

Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.